Volume 25, Number 2—February 2019
Online Report
Public Health–Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union
Adoración Navarro-Torné
, Finnian Hanrahan, Barbara Kerstiëns, Pilar Aguar, and Line Matthiessen
, Finnian Hanrahan, Barbara Kerstiëns, Pilar Aguar, and Line Matthiessen
Table 1
Influenza vaccine–focused projects funded through the seventh Framework Programme for Research and Technological Development of the European Union*
| Project acronym | Project title | Funding scheme | Research focus | Website | Total EU contribution, € |
|---|---|---|---|---|---|
| FP7 projects | |||||
| FLUCOP | Standardization and development of assays for assessment of influenza vaccine correlates of protection | Public private partnership | Immunoassays for correlates of protection | http://www.flucop.eu/ | 6,100,000 |
| IMECS | Identification of mechanisms correlating with susceptibility for avian influenza | Translational collaborative research | Correlates of protection | http://cordis.europa.eu/project/rcn/88172_en.html | 2,797,287 |
| NASPANVAC | Nasal pandemic influenza vaccine | Translational collaborative research | Pandemic influenza vaccine | http://cordis.europa.eu/project/rcn/86777_en.html | 3,573,648 |
| INIMIN | Defense mechanisms of innate immunity against influenza virus | Training and mobility | Innate immunity to influenza | http://cordis.europa.eu/project/rcn/88512_en.html | 225,715 |
| PLAPROVA | Plant production of vaccines | Translational collaborative research | VLP-based influenza vaccine | http://cordis.europa.eu/project/rcn/89887_en.html | 1,998,354 |
| FLUPLAN | Novel strategies to combat future influenza pandemics | Frontier research | MVA-based influenza vaccine | http://cordis.europa.eu/project/rcn/94581_en.html | 2,187,758 |
| IMMUNExplore | New approaches to analyze and exploit the human B and T cell response against viruses | Frontier research | Innate immunity to influenza | http://cordis.europa.eu/project/rcn/95521_en.html | 1,979,200 |
| REPLIXCEL | Highly efficient new generation synthetic RNA replicon–based vaccine | Training and mobility | RNA replicon-based influenza vaccine | http://cordis.europa.eu/project/rcn/94667_en.html | 2,591,172 |
| FERFLU EXPRESS | Investigation of influenza immune responses and vaccine efficacy correlates by global expression profiling and immunological analyses in the ferret model of influenza | Training and mobility | Immune response to influenza vaccine | http://cordis.europa.eu/project/rcn/95964_en.html | 239,693 |
| SIMULATA | System for immunological modeling as an ultimate tool to link adjuvant function to adaptive immune responses | Training and mobility | Immune response to influenza vaccine | http://cordis.europa.eu/project/rcn/95337_en.html | 220,500 |
| FLUPIG | Pathogenesis and transmission of influenza virus in pigs | Translational collaborative research | Pandemic influenza vaccine | http://www.flupig.ugent.be/ | 4,854,452 |
| TCDIFLU | Impact of adjuvants on T cell differentiation after influenza vaccination analyzed at the single cell level | Training and mobility | Immune response to influenza vaccine | http://cordis.europa.eu/project/rcn/98379_en.html | 180,084 |
| INFLUENZA PREDICTION | Phylogenetic prediction of the evolutionary trajectory of the influenza virus | Training and mobility | Seasonal influenza modeling | http://cordis.europa.eu/project/rcn/104037_en.html | 209,033 |
| ARCAS | ARCAS: Analysis of the route to commercialization of MVA-based influenza vaccines | Frontier research | MVA-based influenza vaccine | http://cordis.europa.eu/project/rcn/105989_en.html | 149,840 |
| MAJARVISCIG | A single dose, cytomegalovirus-based vaccine to induce heterosubtypic protective immunity to influenza A virus | Training and mobility | Immune response to influenza vaccine | http://cordis.europa.eu/project/rcn/107995_en.html | 100,000 |
| UNIVAX | A “universal” influenza vaccine through synthetic, dendritic cell–targeted, self-replicating RNA vaccines | Translational collaborative research | RNA replicon-based influenza vaccine | http://www.univax-fp7.eu/index.php?id = 1293 | 5,999,457 |
| UNISEC | Universal influenza vaccines secured | Translational collaborative research | Influenza vaccine development platform | http://www.unisecconsortium.eu/ | 5,972,181 |
| FLUTCORE | Development of a universal influenza vaccine based on tandem core technology | Translational collaborative research | Tandem core technology for influenza vaccine | http://www.flutcore.eu/ | 3,162,304 |
| FLUNIVAC | Influenza virus universal vaccine development program | Translational collaborative research | MVA-based influenza vaccine | http://flunivac.eu/ | 5,066,881 |
| EDUFLUVAC | Combinatorial immunization strategy to educate the immune system toward cross-recognition and coverage against antigenic drift in seasonal influenza virus exposure | Translational collaborative research | VLP-based influenza vaccine | http://www.edufluvac.eu/ | 4,647,149 |
| UNIVACFLU | Universal flu vaccine | Training and mobility | European training platform for influenza vaccines | http://cordis.europa.eu/project/rcn/109828_en.html | 4,116,701 |
| IRINVAC | Immune responses to influenza vaccine | Training and mobility | Immune response to influenza vaccine | http://cordis.europa.eu/project/rcn/109387_en.html | 100,000 |
| FLU-MAL VLP | Chimeric influenza-VLP used as vaccine platform for presentation of foreign antigens: application to malaria antigens | Training and mobility | VLP-based influenza vaccine | http://cordis.europa.eu/project/rcn/186122_en.html | 194,047 |
| SAMUFLU | Self-amplifying RNA technology applied to the development of a universal influenza vaccine | Training and mobility | RNA replicon-based influenza vaccine | http://cordis.europa.eu/project/rcn/188000_en.html | 187,415 |
| ADITEC |
Advanced immunization technologies |
Translational collaborative research |
Immune response to influenza vaccine |
http://www.aditecproject.eu/ |
29,980,670 |
| Horizon 2020 projects | |||||
| BROADimmune | Structural, genetic, and functional analyses of broadly neutralizing antibodies against human pathogens | Frontier research | Neutralizing antibodies | https://cordis.europa.eu/project/rcn/198722_en.html#result-217092 | 1,867,500 |
| DRIVE | Development of robust and innovative vaccine effectiveness | Public private partnership | Effectiveness studies of influenza vaccines | https://www.drive-eu.org/ | 8,999,812.50 |
| I-MOVE+ | Integrated Monitoring of Vaccines in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly | Translational collaborative research | Comparative effectiveness, impact of vaccines | http://www.i-moveplus.eu/ | 7,482,729 |
| FluPRINT | Tracing the influenza vaccine imprint on immune system to identify cellular signature of protection | Training and mobility | Cellular immune response to influenza vaccine in children | https://cordis.europa.eu/project/rcn/215465_en.html | 269,858 |
| UNIFLUVAC | A novel universal influenza vaccine targeting epitopes of limited variability | Frontier research | Epitopes of limited variability in novel influenza vaccine | https://cordis.europa.eu/project/rcn/218373_en.html | 149,297 |
*MVA, modified vaccinia virus Ankara; VLP, virus-like particle.
Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.